AU2003295653B2 - Use of HMGB polypeptides for increasing immune responses - Google Patents

Use of HMGB polypeptides for increasing immune responses Download PDF

Info

Publication number
AU2003295653B2
AU2003295653B2 AU2003295653A AU2003295653A AU2003295653B2 AU 2003295653 B2 AU2003295653 B2 AU 2003295653B2 AU 2003295653 A AU2003295653 A AU 2003295653A AU 2003295653 A AU2003295653 A AU 2003295653A AU 2003295653 B2 AU2003295653 B2 AU 2003295653B2
Authority
AU
Australia
Prior art keywords
polypeptide
box
hmgb
antibody
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003295653A
Other languages
English (en)
Other versions
AU2003295653A1 (en
Inventor
Kevin J. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of AU2003295653A1 publication Critical patent/AU2003295653A1/en
Application granted granted Critical
Publication of AU2003295653B2 publication Critical patent/AU2003295653B2/en
Assigned to FEINSTEIN INSTITUTE OF MEDICAL RESEARCH reassignment FEINSTEIN INSTITUTE OF MEDICAL RESEARCH Request for Assignment Assignors: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE
Assigned to THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH reassignment THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH Request for Assignment Assignors: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003295653A 2002-11-20 2003-11-19 Use of HMGB polypeptides for increasing immune responses Ceased AU2003295653B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42784802P 2002-11-20 2002-11-20
US60/427,848 2002-11-20
PCT/US2003/036975 WO2004046338A2 (en) 2002-11-20 2003-11-19 Use of hmgb polypeptides for increasing immune responses

Publications (2)

Publication Number Publication Date
AU2003295653A1 AU2003295653A1 (en) 2004-06-15
AU2003295653B2 true AU2003295653B2 (en) 2007-08-16

Family

ID=32326601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295653A Ceased AU2003295653B2 (en) 2002-11-20 2003-11-19 Use of HMGB polypeptides for increasing immune responses

Country Status (6)

Country Link
US (1) US20060121047A1 (https=)
EP (1) EP1567544A4 (https=)
JP (1) JP2006506441A (https=)
AU (1) AU2003295653B2 (https=)
CA (1) CA2505682A1 (https=)
WO (1) WO2004046338A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
US8227417B2 (en) * 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
MX2012010793A (es) 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
EP2613797B1 (en) * 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
JP6778681B2 (ja) 2014-12-12 2020-11-04 ザ ファインスタイン インスティテュート フォー メディカル リサーチ Ｈｍｇｂ１媒介性炎症の治療
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
SG11202103001PA (en) * 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
US20250101204A1 (en) * 2022-02-28 2025-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for protecting against cell damage and inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU2001245823A1 (en) * 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US20030014155A1 (en) * 2001-07-12 2003-01-16 Applied Material, Inc. High temperature substrate transfer robot

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Andersson et al, High mobility group 1 protein (HMG-1) stimulates pro-inflammatory cytokine synthesis in human monocytes, Journal of Experimental Medicine, vol.192 (4) 2000 *
Wen et al, A human placental cDNA clone that encodes non-histone chromosomal protein HMG-1, Nucleic Acid Research, vol.17 (3), 1989 *

Also Published As

Publication number Publication date
CA2505682A1 (en) 2004-06-03
AU2003295653A1 (en) 2004-06-15
EP1567544A2 (en) 2005-08-31
JP2006506441A (ja) 2006-02-23
US20060121047A1 (en) 2006-06-08
WO2004046338A3 (en) 2004-09-16
WO2004046338A2 (en) 2004-06-03
EP1567544A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
AU2003295653B2 (en) Use of HMGB polypeptides for increasing immune responses
CN110461871B (zh) 白蛋白结合结构域融合蛋白
KR100894359B1 (ko) 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
KR0183035B1 (ko) 사람 사이토킨 합성 억제 인자 및 이의 길항제
AU2002309829B2 (en) Use of HMG fragment as anti-inflammatory agents
JP2005512507A6 (ja) 抗炎症剤としてのｈｍｇフラグメントの使用
US20030099647A1 (en) Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JPH09501572A (ja) 精製された霊長類ｃｔｌａ−８抗原および関連する試薬
CN110392695A (zh) 针对cd127的抗体和多肽
TW200916482A (en) Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same
JP2001503014A (ja) 防御免疫応答を増強するための方法
JPH09512172A (ja) 保護的免疫応答及びｉｌ−１２産生の刺激及び促進のための化合物及び方法
JP2009131263A (ja) ５０個のヒト分泌タンパク質
JP3223260B2 (ja) Ｔ細胞増殖促進因子
AU758576C (en) Chemokines with amino-terminal modifications
JP2001509373A (ja) 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法
KR100483480B1 (ko) Ｍｈｃ 클래스 ⅰ과 ｍｈｃ 클래스 ⅱ 분자에 결합하는,ｎｙ-ｅｓｏ-1의 아미노산 서열에 상응하는 분리된펩티드, 및 그것의 사용
US20040156851A1 (en) HMGB1 combination therapies
JP2023145622A (ja) ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５
CA2386248A1 (en) Il13 mutants
JP2009280620A (ja) 哺乳動物ランゲルハンス細胞抗原に対する抗体およびそれらの使用
JP2001231578A (ja) Ｉｌ−１ファミリーに属する蛋白質
JP2003508525A (ja) 抗腫瘍抗体、タンパク質、及びそれらの使用
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
JP2024531823A (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

Free format text: FORMER NAME: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE

TC Change of applicant's name (sec. 104)

Owner name: THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

Free format text: FORMER NAME: FEINSTEIN INSTITUTE OF MEDICAL RESEARCH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired